VisionCare Appoints Industry Veterans, Mark Forchette, and John Ryan of ONSET
Ventures to its Board of Directors
SARATOGA, Calif., April 15, 2014
SARATOGA, Calif., April 15, 2014 /PRNewswire/ -- VisionCare Ophthalmic
Technologies, Inc., a developer of advanced visual prosthetic devices for the
treatment of age-related macular degeneration, today announced two changes to
its Board of Directors. Ophthalmic industry veteran, Mark Forchette has joined
the board in a new seat; John Ryan is filling ONSET Ventures existing board
Mark Forchette brings thirty years of experience in ophthalmic sales,
marketing and business unit management, and has driven commercial success at
three ophthalmic companies. Mr. Forchette joined OptiMedica in 2007 as
President and Chief Executive Officer. Under Mr. Forchette's direction and
leadership, the company developed and launched breakthrough technologies in
the retinal laser photocoagulation market and the femtosecond laser cataract
surgical market. OptiMedica's retina and glaucoma segment was acquired by
TopCon Corporation of Japan in 2010; its laser cataract surgical business was
acquired by Abbott Laboratories in 2013. Prior to OptiMedica, Mr. Forchette
held executive sales and marketing positions at Alcon and Swiss company,
Grieshaber & Co., Inc. Mr. Forchette received a B.S. in Marketing from Auburn
University and completed the Harvard Program for Management Development. He
currently serves on the Deans Advisory Council of the Harbert School of
Business at Auburn University.
"We are very pleased to have Mark join our Board of Directors," commented
Allen W. Hill, VisionCare's President and CEO. "His deep understanding of the
ophthalmic market and experience working with retinal and anterior segment
surgeons will help VisionCare drive continued adoption of our CentraSight
treatment program and provide life-changing therapy to end-stage AMD
"VisionCare's telescope implant is impressive technology that is already
making a significant difference in the quality of patients' lives. I am
excited to be part of this team to help insure that patients with the advanced
form of macular degeneration that can benefit from CentraSight are able to
experience the remarkable improvements in quality of life that this technology
can deliver," stated Mr. Forchette.
John Ryan is a partner at ONSET Ventures. He has spent over 20 years focused
on the founding, building and financing of companies across many sectors of
the healthcare industry at stages ranging from the earliest company formation
to the largest industry leaders. Prior to ONSET, Mr. Ryan led the venture
investing efforts in the medical device sector for Panorama Capital, JPMorgan
Partners and Chase Capital Partners. Prior to that, he worked with Morgan
Stanley Venture Partners and before that with Morgan Stanley's healthcare
investment banking group.
Mr. Ryan is a board member for Relievant, Valeritas and Vertos Medical. He
also serves on the board of organizations such as Mills-Peninsula Health
Services hospital organization (a Sutter Health affiliate) and the University
of Colorado Technology Transfer Office. Mr. Ryan holds an M.B.A. from the
Harvard Business School and a Bachelor of Science degree with high honors from
the University of Colorado.
"ONSET Ventures has been behind us since our early days and we are very
pleased to have John Ryan join our board," said Mr. Hill.
VisionCare Ophthalmic Technologies, Inc., headquartered in Saratoga, CA, is a
privately-held company focused on development, manufacturing, and marketing of
implantable ophthalmic devices and technologies that are intended to
significantly improve vision and quality of life for individuals with
end-stage age-related macular degeneration. VisionCare's Implantable Miniature
Telescope was invented by company founders Yossi Gross and Isaac Lipshitz.
Information on VisionCare can be found at www.visioncareinc.net.
About the CentraSight Treatment Program
CentraSight is a first-of-kind treatment program that utilizes a tiny
telescope implant for end-stage age-related macular degeneration (AMD), the
most advanced form of AMD and the leading cause of blindness in older
Americans. Patients with End-stage AMD have a central blind spot or missing
area in their vision that makes it difficult or impossible to see faces, read,
and perform everyday activities. The CentraSight treatment program allows
patients to see details again by implanting a tiny telescope in the eye in an
outpatient procedure, then coordinating with low vision specialists to help
the patient learn how to use their new vision for everyday activities.
Patients and physicians can learn more by visiting www.CentraSight.com or
About ONSET Ventures
ONSET Ventures specializes in providing start-up, follow-on, and intellectual
capital to entrepreneurs and early-stage technology ventures. ONSET helps
transform world-class ideas into sustainable and valuable businesses, through
a process of "venture craftsmanship." The firm has partnered with start-ups
since 1984 and has more than $1 billion under management. ONSET Ventures is
located in Menlo Park, California. For more information, visit:
SOURCE VisionCare Ophthalmic Technologies, Inc.
Contact: Allen Hill, President and CEO, or Richard Powers, Executive Vice
President, VisionCare Ophthalmic Technologies, Inc., (408) 872-9393,
Press spacebar to pause and continue. Press esc to stop.